Female Reproductive System Transitional Cell Carcinoma

Female Reproductive System Transitional Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

27 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 9
Recruiting: 1
Ph III recruiting: 1
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02020707	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	completed	Phase 1	43	Mayo ClinicOTHER	1	Jul 26, 2024	clinicaltrials
NCT00989651	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	completed	Phase 1	431	National Cancer Institute (NCI)NIH	1	Oct 20, 2021